原发与继发性骨髓纤维化的基因组分析重新定义ASXL1突变的预后影响:FIM研究
该研究纳入479例来自法国FIM 24个中心的骨髓纤维化患者,对77个基因进行高通量测序,用贝叶斯网络识别基因组分组,并在多状态模型中分析预后影响,另用276例独立队列验证。结果识别出4个基因组分组,TP53突变组和高危基因突变组与白血病转化和死亡风险增加相关,而单纯ASXL1突变无预后价值,但ASXL1突变合并TP53或高危基因突变时预后更差。
要点
- TP53突变组白血病转化风险显著增加(HR 8.68,95%CI 3.32-22.73)。
- 高危基因突变组白血病转化风险增加(HR 3.24,95%CI 1.58-6.64)。
- 单纯ASXL1突变无预后价值,但合并TP53或高危基因突变时预后更差。
核心结论
- TP53突变和高危基因突变与白血病转化及死亡风险增加相关。
- 单纯ASXL1突变无预后价值,但合并TP53或高危基因突变时预后更差。
- 研究提出骨髓纤维化不良突变新定义,将TP53、CBL、NRAS、KRAS和U2AF1加入既往基因列表。
研究设计与样本
- 研究纳入479例来自法国FIM 24个中心的骨髓纤维化患者。
- 对77个基因进行高通量测序,用贝叶斯网络识别基因组分组。
- 采用多状态模型分析骨髓纤维化、急性白血病和死亡之间的转换。
- 结果在276例独立已发表队列中验证。
主要发现
- 识别出4个基因组分组:TP53突变组、高危基因突变组、单纯ASXL1突变组和其他患者。
- TP53突变组白血病转化HR为8.68(95%CI 3.32-22.73),骨髓纤维化死亡HR为3.03(95%CI 1.66-5.56)。
- 高危基因突变组白血病转化HR为3.24(95%CI 1.58-6.64),骨髓纤维化死亡HR为1.77(95%CI 1.18-2.67)。
- 单纯ASXL1突变无预后价值,验证队列确认。
- ASXL1突变合并TP53或高危基因突变时预后更差。
关键数值与推荐
- 高危基因突变定义为EZH2、CBL、U2AF1、SRSF2、IDH1、IDH2、NRAS或KRAS中至少1个突变。
临床怎么用
- 骨髓纤维化患者应进行包含TP53、CBL、NRAS、KRAS和U2AF1的基因检测以评估预后。
- 单纯ASXL1突变不应视为不良预后因素,但需评估是否合并TP53或高危基因突变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to study the prognostic impact of the mutational landscape in primary and secondary myelofibrosis. The study included 479 patients with myelofibrosis recruited from 24 French Intergroup of Myeloproliferative Neoplasms (FIM) centers. The molecular landscape was studied by high-throughput sequencing of 77 genes. A Bayesian network allowed the identification of genomic groups whose prognostic impact was studied in a multistate model considering transitions from the 3 conditions: myelofibrosis, acute leukemia, and death. Results were validated using an independent, previously published cohort (n = 276). Four genomic groups were identified: patients with TP53 mutation; patients with ≥1 mutation in EZH2, CBL, U2AF1, SRSF2, IDH1, IDH2, NRAS, or KRAS (high-risk group); patients with ASXL1-only mutation (ie, no associated mutation in TP53 or high-risk genes); and other patients. A multistate model found that both TP53 and high-risk groups were associated with leukemic transformation (hazard ratios [HRs] [95% confidence interval], 8.68 [3.32-22.73] and 3.24 [1.58-6.64], respectively) and death from myelofibrosis (HRs, 3.03 [1.66-5.56] and 1.77 [1.18-2.67], respectively). ASXL1-only mutations had no prognostic value that was confirmed in the validation cohort. However, ASXL1 mutations conferred a worse prognosis when associated with a mutation in TP53 or high-risk genes. This study provides a new definition of adverse mutations in myelofibrosis with the addition of TP53, CBL, NRAS, KRAS, and U2AF1 to previously described genes. Furthermore, our results argue that ASXL1 mutations alone cannot be considered detrimental.
引用
- Luque Paz D, Riou J, Verger E, et al. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021. PMID: 33666653. doi:10.1182/bloodadvances.2020003444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。